OPINION: Going Local in Health Innovation – It is time and we are ready

OPINION: Going Local in Health Innovation – It is time and we are ready

The COVID-19 pandemic has reinforced the need to think global and build locally. The African innovative pharmaceutical sector has the potential to thrive and needs more incentive to grow. A blooming continental sector would serve as a critical and secure source for key vaccines and therapeutics, reducing the need to rely on the goodwill of donors, writes Professor Kelly Chibale.

Read More

In-depth: What will it take to actually make mRNA vaccines in SA

In-depth: What will it take to actually make mRNA vaccines in SA

Messenger RNA (mRNA) vaccines, such as the COVID-19 vaccines made by Moderna and Pfizer/BioNTech, have been hailed for their manufacturing advantages over conventional vaccines – so much so that African leaders such as President Cyril Ramaphosa has called for mRNA production capacity to be developed in Africa. Catherine Tomlinson examines why mRNA vaccines are easier to make than some other types of vaccines and asks what it will take to build such production capacity.

Read More

In-depth: Promising signs for local biopharmaceutical production

In-depth: Promising signs for local biopharmaceutical production

Biopharmaceuticals are therapeutic drugs, vaccines, and diagnostics in which the active ingredient is produced in a living substance such as eggs or tobacco plants. The living substance acts as a ‘miniature factory’ in which the active ingredient is grown and replicated. Catherine Tomlinson takes a deep dive into the fascinating research and other initiatives in South Africa aimed at spurring local production of these products – and asks why a Cape Town-based company opted to set up a manufacturing plant in Mauritius rather than at home.

Read More

In-depth: After a rough 17 years, is Biovac finally on track?

In-depth: After a rough 17 years, is Biovac finally on track?

South Africa has struggled to secure adequate stock of urgently needed COVID-19 vaccines. This has raised questions about the state of the country’s local vaccine manufacturing capacity and why, after almost two decades of government support, South Africa’s partially state-owned vaccine manufacturer Biovac is not better positioned to respond to the pandemic. Catherine Tomlinson investigates.

Read More